ID   HT-29 BR100
AC   CVCL_DH88
SY   HT29 BR100; BR100
DR   cancercelllines; CVCL_DH88
DR   GEO; GSM736968
DR   Progenetix; CVCL_DH88
DR   Wikidata; Q54896509
RX   PubMed=22216088;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:52717; Bortezomib (Velcade).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Colon; UBERON=UBERON_0001155.
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0320 ! HT-29
SX   Female
AG   44Y
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 05-10-23; Version: 17
//
RX   PubMed=22216088; DOI=10.1371/journal.pone.0027996;
RA   Suzuki E., Demo S., Deu E., Keats J.J., Arastu-Kapur S., Bergsagel P.L.,
RA   Bennett M.K., Kirk C.J.;
RT   "Molecular mechanisms of bortezomib resistant adenocarcinoma cells.";
RL   PLoS ONE 6:E27996-E27996(2011).
//